Development of a Rapid Diagnostic Kit for Congestive Heart Failure Using Recombinant NT-proBNP Antigen

Lee, Young-Ki; Dong-Ok, Choi; Kim, Ga Yeon

doi:10.3390/medicina57080751

Cited by 4 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One potential current application of biohumoral testing for sudden cardiac death is the development of rapid test kits [ 168 ], which, due to their ease of use, would increase accessibility of screening in the absence of other methods available in some cases.…”

Section: Discussionmentioning

confidence: 99%

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review

Isailă,

Moroianu,

Hostiuc

2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Sudden cardiac death (SCD) represents a challenge to health systems globally and is met with increased frequency in the population. Over time, multiple screening methods have been proposed, including the analysis of various plasma biomarkers. This article aims to analyze for illustrative purposes the specialized literature in terms of current biomarkers and testing trends, in the case of cardiovascular diseases and implicitly sudden cardiac death. Materials and Methods: In this regard, we searched the PubMed database from 2010 to the present time using the keywords “sudden cardiac death” and “biomarkers”. The inclusion criteria were clinical trials that analyzed the effectiveness of screening methods in terms of biomarkers used in stratifying the risk of cardiac distress and/or sudden cardiac death. We excluded reviews, meta-analyses, and studies looking at the effectiveness of treatments. Results: An extended approach was found, through studies that brought to the forefront both classical markers analyzed by new, more performant methods, markers for other pathologies that also determined cardiovascular impact, non-specific molecules with effects on the cardiovascular system, and state-of-the-art markers, such as microRNA. Some molecules were analyzed simultaneously in certain groups of patients. Conclusion: The observed current trend revealed the tendency to define the clinical-biological particularities of the person to be screened.

show abstract

Section: Discussionmentioning

confidence: 99%

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review

Isailă,

Moroianu,

Hostiuc

2024

Medicina

View full text Add to dashboard Cite

show abstract

“…The kit demonstrated excellent reactivity, showing high specificity and its potential to assess HF risk early. [ 11 ] Galectin-3 was also used in another study that showed higher sensitivity (94.3%), but lower specificity (65.1%) compared with BNP (77.1%) in diagnosing HF in patients with preserved ejection fraction. Additionally, the areas under the receiver operating characteristic curve for galectin-3 and BNP were 0.891 and 0.896, respectively.…”

Section: Biomarkers To Diagnose Heart Failurementioning

confidence: 99%

Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review

Alzaabi,

Abdelsalam,

Alhammadi

et al. 2024

Card Fail Rev

View full text Add to dashboard Cite

There is a high prevalence of heart failure (HF) worldwide, which has significant consequences for healthcare costs, patient death and quality of life. Therefore, there has been much focus on finding and using biomarkers for early diagnosis, prognostication and therapy of HF. This overview of the research presents a thorough examination of the current state of HF biomarkers and their many uses. Their function in diagnosing HF, gauging its severity and monitoring its response to therapy are all discussed. Particularly promising in HF diagnosis and risk stratification are the cardiac-specific biomarkers, B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Markers of oxidative stress, extracellular matrix, renal function, inflammation and cardiac peptides have shown promise in evaluating HF severity and prognosis. MicroRNAs and insulin-like growth factor are two emerging biomarkers that have shown potential in helping with HF diagnosis and prognosis.

show abstract

“…Typically, small amounts of BNP are found in the blood, and high levels are correlated to the insufficient capability of the heart in pumping blood. Due to the significance of BNP, a team of authors has created a quick colorimetric diagnostic kit based on an interaction between NT-ProBNP and a specific antigen [49].…”

Section: Datasetmentioning

confidence: 99%

Deep Learning for Predicting Congestive Heart Failure

et al. 2022

View full text Add to dashboard Cite

Congestive heart failure (CHF) is one of the most debilitating cardiac disorders. It is a costly disease in terms of both lives and financial outlays, given the high rate of hospital re-admissions and mortality. Heart failure (HF) is notoriously difficult to identify on time, and is frequently accompanied by additional comorbidities that further complicate diagnosis. Many decision support systems (DSS) have been developed to facilitate diagnosis and to raise the standard of screening and monitoring operations, even for non-expert staff. This is confirmed in the literature by records of highly performing diagnosis-aid systems, which are unfortunately not very relevant to expert cardiologists. In order to assist cardiologists in predicting the trajectory of HF, we propose a deep learning-based system which predicts severity of disease progression by employing medical patient history. We tested the accuracy of four models on a labeled dataset, composed of 1037 records, to predict CHF severity and progression, achieving results comparable to studies based on much larger datasets, none of which used longitudinal multi-class prediction. The main contribution of this work is that it demonstrates that a fairly complicated approach can achieve good results on a medium size dataset, providing a reasonably accurate means of determining the evolution of CHF well in advance. This potentially constitutes a significant aid for healthcare managers and expert cardiologists in designing different therapies for medication, healthy lifestyle changes and quality of life (QoL) management, while also promoting allocation of resources with an evidence-based approach.

show abstract

Development of a Rapid Diagnostic Kit for Congestive Heart Failure Using Recombinant NT-proBNP Antigen

Cited by 4 publications

References 29 publications

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review

Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review

Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review

Deep Learning for Predicting Congestive Heart Failure

Contact Info

Product

Resources

About